Oculis prices $100 million offering

Swiss biotech Oculis Holding (Nasdaq: OCS) yesterday announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses.

The company noted that the oversubscribed offering is expected to close on or about February 18, 2025, subject to satisfaction of customary closing conditions.

Oculis intends to use the net proceeds from the offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate privosegtor (OCS-05), as well as for working capital and general corporate purposes.